COMMUNIQUÉS West-GlobeNewswire

-
BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
05/11/2018 - 13:00 -
Intercept Announces New OCA Data to be Presented at The Liver Meeting® 2018
05/11/2018 - 13:00 -
Ziopharm Oncology to Present Update on Controlled IL-12 Brain Cancer Trial at Annual Meeting of the Society for Neuro-Oncology on Nov. 16
05/11/2018 - 13:00 -
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Corporate Highlights
05/11/2018 - 13:00 -
Breathtec Provides Update on FAIMS Breathalyzer Development Program
05/11/2018 - 13:00 -
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
05/11/2018 - 13:00 -
Amicus Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Updates
05/11/2018 - 13:00 -
BioCryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology
05/11/2018 - 13:00 -
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2018 Financial Results and Host Conference Call on November 12
05/11/2018 - 13:00 -
Abeona Therapeutics and REGENXBIO Announce Worldwide Exclusive Licenses for the Treatment of Four Rare Lysosomal Storage Disorders Using NAV AAV9 Vector
05/11/2018 - 13:00 -
Arcturus Therapeutics Hosts Ribbon Cutting Ceremony for its Research and Development Facility
05/11/2018 - 13:00 -
Dova Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for DOPTELET® (avatrombopag) for the Treatment of Chronic Immune Thrombocytopenia (ITP)
05/11/2018 - 13:00 -
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
05/11/2018 - 13:00 -
AnaptysBio to Participate in Upcoming Investor Conferences
05/11/2018 - 12:30 -
Flexion Therapeutics Announces Product-Specific J Code (J3304) for ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) Effective January 1, 2019
05/11/2018 - 12:30 -
Alpha Pro Tech, Ltd. Announces Financial Results for the Third Quarter and Nine Months Ended September 30, 2018
05/11/2018 - 12:30 -
Invitation to investor meeting on November 8, 2018
05/11/2018 - 12:16 -
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
05/11/2018 - 12:00 -
Capital Senior Living Corporation to Present at the Stephens NY Investment Conference on Wednesday, November 7, 2018
05/11/2018 - 12:00
Pages